Guillaume Mouillet1,2,3, Antoine Falcoz4,5, Joëlle Fritzsch4,5, Hamadi Almotlak6, Pascale Jacoulet7, Xavier Pivot8, Cristian Villanueva9, Laura Mansi6,5, Stefano Kim6,5, Elsa Curtit6,5, Nathalie Meneveau6, Olivier Adotevi6,5, Marine Jary6,5, Guillaume Eberst5,7, Angelique Vienot6,5, Fabien Calcagno6, Astrid Pozet4,5, Oumelkheir Djoumakh4,5, Christophe Borg6,5, Virginie Westeel4,5,7, Amélie Anota4,5,10, Sophie Paget-Bailly4,5. 1. Methodological and Quality of Life Unit in Oncology, University Hospital of Besançon, 25000, Besançon, France. gmouillet@chu-besancon.fr. 2. Department of Medical Oncology, University Hospital of Besançon, Boulevard Fleming, 25000, Besançon, France. gmouillet@chu-besancon.fr. 3. INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France. gmouillet@chu-besancon.fr. 4. Methodological and Quality of Life Unit in Oncology, University Hospital of Besançon, 25000, Besançon, France. 5. INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France. 6. Department of Medical Oncology, University Hospital of Besançon, Boulevard Fleming, 25000, Besançon, France. 7. Respiratory Medicine Department, University Hospital of Besançon, 25000, Besançon, France. 8. Institut de Cancérologie Strasbourg Europe, Strasbourg, France. 9. Centre de Cancérologie de Grand Montpellier, 34040, Montpellier, France. 10. French National Platform Quality of Life and Cancer, Besançon, France.
Abstract
INTRODUCTION: Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical care with real-time feedback to physicians could help to enhance patient-centered care. We evaluated the feasibility of REMOQOL in the French context in the QOLIBRY study. The primary objective was to assess the patients' compliance with REMOQOL. METHODS: The QOLIBRY study was a single-center, prospective study conducted in the University Hospital of Besançon (France). Eligible patients were those treated with systemic therapies for breast, lung or colorectal cancer at any stage. Patients were invited to complete the EORTC QLQ-C30 questionnaire and cancer-site-specific modules before each visit on tablets and/or computers in the hospital or at home. During the consultation, physicians had real-time access to visual summaries of HRQoL scores. Compliance was assessed as adequate if at least 66% of HRQoL assessments were completed during the 4 months of follow-up. RESULTS: Between March 2016 and October 2018, 177 patients were included in the QOLIBRY study. Median age was 64 years (IQR 54-71). The proportion of patients with an adequate compliance rate was 95.5% (n = 63) in the breast cancer cohort, 98.2% (n = 55) in the colorectal cancer cohort, and 90.9% (n = 50) in the lung cancer cohort. The physicians checked the HRQoL results in 73.1% of visits and prescribed supportive care and adapted patient management in 8.3% and 5.2% of visits, respectively. CONCLUSION & PERSPECTIVES: The results of QOLIBRY study suggest that REMOQOL is feasible in the French context. However, information about HRQoL monitoring, training of the physicians in the use of the software, and recommendations for using HRQoL results to guide care are essential and must be improved.
INTRODUCTION: Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical care with real-time feedback to physicians could help to enhance patient-centered care. We evaluated the feasibility of REMOQOL in the French context in the QOLIBRY study. The primary objective was to assess the patients' compliance with REMOQOL. METHODS: The QOLIBRY study was a single-center, prospective study conducted in the University Hospital of Besançon (France). Eligible patients were those treated with systemic therapies for breast, lung or colorectal cancer at any stage. Patients were invited to complete the EORTC QLQ-C30 questionnaire and cancer-site-specific modules before each visit on tablets and/or computers in the hospital or at home. During the consultation, physicians had real-time access to visual summaries of HRQoL scores. Compliance was assessed as adequate if at least 66% of HRQoL assessments were completed during the 4 months of follow-up. RESULTS: Between March 2016 and October 2018, 177 patients were included in the QOLIBRY study. Median age was 64 years (IQR 54-71). The proportion of patients with an adequate compliance rate was 95.5% (n = 63) in the breast cancer cohort, 98.2% (n = 55) in the colorectal cancer cohort, and 90.9% (n = 50) in the lung cancer cohort. The physicians checked the HRQoL results in 73.1% of visits and prescribed supportive care and adapted patient management in 8.3% and 5.2% of visits, respectively. CONCLUSION & PERSPECTIVES: The results of QOLIBRY study suggest that REMOQOL is feasible in the French context. However, information about HRQoL monitoring, training of the physicians in the use of the software, and recommendations for using HRQoL results to guide care are essential and must be improved.
Authors: Andrew Bottomley; Madeline Pe; Jeff Sloan; Ethan Basch; Franck Bonnetain; Melanie Calvert; Alicyn Campbell; Charles Cleeland; Kim Cocks; Laurence Collette; Amylou C Dueck; Nancy Devlin; Hans-Henning Flechtner; Carolyn Gotay; Eva Greimel; Ingolf Griebsch; Mogens Groenvold; Jean-Francois Hamel; Madeleine King; Paul G Kluetz; Michael Koller; Daniel C Malone; Francesca Martinelli; Sandra A Mitchell; Carol M Moinpour; Jammbe Musoro; Daniel O'Connor; Kathy Oliver; Elisabeth Piault-Louis; Martine Piccart; Francisco L Pimentel; Chantal Quinten; Jaap C Reijneveld; Christoph Schürmann; Ashley Wilder Smith; Katherine M Soltys; Martin J B Taphoorn; Galina Velikova; Corneel Coens Journal: Lancet Oncol Date: 2016-10-18 Impact factor: 41.316
Authors: Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Donna L Berry; Fangxin Hong; Barbara Halpenny; Ann H Partridge; Jesse R Fann; Seth Wolpin; William B Lober; Nigel E Bush; Upendra Parvathaneni; Anthony L Back; Dagmar Amtmann; Rosemary Ford Journal: J Clin Oncol Date: 2013-12-16 Impact factor: 44.544
Authors: Milena Anatchkova; Sarah M Donelson; Anne M Skalicky; Colleen A McHorney; Dayo Jagun; Jennifer Whiteley Journal: J Patient Rep Outcomes Date: 2018-12-27
Authors: Sarah King; Josephine Exley; Sarah Parks; Sarah Ball; Teresa Bienkowska-Gibbs; Calum MacLure; Emma Harte; Katherine Stewart; Jody Larkin; Andrew Bottomley; Sonja Marjanovic Journal: Qual Life Res Date: 2016-04-02 Impact factor: 4.147